Rigrodsky & Long, P.A. Announces Investigation Of Amylin Pharmaceuticals, Inc. Buyout
July 02 2012 - 11:45AM
Business Wire
Rigrodsky & Long, P.A. announces that it is investigating
potential legal claims against the board of directors of Amylin
Pharmaceuticals, Inc. (“Amylin” or the “Company”) (NASDAQ GS: AMLN)
regarding possible breaches of fiduciary duties and other
violations of law related to the Company’s entry into an agreement
to be acquired by Bristol-Myers Squibb Company (“Bristol-Myers”)
(NYSE: BMY) in a transaction valued at approximately $7 billion,
including debt and a contractual payment obligation to Eli Lilly
& Company.
Click here to learn more:
http://www.rigrodskylong.com/investigations/amylin-pharmaceuticals-inc-amln.
Under the terms of the proposal, public shareholders of Amylin
will receive will receive $31.00 per share in cash for each share
of Amylin they own.
The investigation concerns whether Amylin’s board of directors
failed to adequately shop the Company and obtain the best possible
value for Amylin’s shareholders before entering into an agreement
with Bristol-Myers. According to Yahoo! Finance, at least one
analyst has set a price target for Amylin stock at $32.00 per
share.
If you own the common stock of Amylin and purchased your shares
before July 2, 2012, if you have information or would like to learn
more about these claims, or if you wish to discuss these matters or
have any questions concerning this announcement or your rights or
interests with respect to these matters, please contact Peter
Allocco at Rigrodsky & Long, P.A., 825 East Gate Boulevard,
Suite 300, Garden City, New York 11530 toll free at (888) 969-4242,
by e-mail to info@rigrodskylong.com, or at:
http://www.rigrodskylong.com/investigations/amylin-pharmaceuticals-inc-amln.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware
and Garden City, New York, regularly prosecutes securities class,
derivative and direct actions, shareholder rights litigation and
corporate governance litigation, on behalf of shareholders in
states and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar
outcome.
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024